Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeLaminate Medical TechnologiesVasQ™ External Support Demonstrates Significant Improvement in Fistula Usability in the Newly...

VasQ™ External Support Demonstrates Significant Improvement in Fistula Usability in the Newly Published Multi-Center Randomized-Controlled Study

August 26, 2019

Laminate Medical Technologies (Laminate) has announced that the American Journal of Kidney Disease has published the first multi-center, the randomized-controlled study of the VasQ External Support for newly created arteriovenous fistulas in hemodialysis patients. Arteriovenous fistulas are the standard of care for the delivery of life-sustaining hemodialysis but also carry the highest rate of failure to develop into functional dialysis accesses. The results of the newly published study demonstrate a significant improvement in fistulas becoming functional with VasQ as compared to the standard of care.

The randomized-controlled study was designed to evaluate the safety and efficacy of VasQ in improving the Short and Mid-term outcomes of arteriovenous fistulas for hemodialysis versus the standard of care. The study enrolled 40 patients randomized 1:1 and followed for 6 months. The study was conducted at Guy’s and St Thomas’ NHS Foundation Trust (London, UK); Southmead Hospital – NHS (North Bristol, UK); St. George’s University Hospitals Foundation Trust (London, UK) ; and Sheba Medical Center (Ramat Gan, Israel).

The outcomes demonstrated significant improvement in functional patency with increased intra-luminal vein diameters in the cannulation segment (a key factor to enable good fistula function) at 3-months post fistula creation. Conversely, stenosis (the leading cause of fistula failure) occurred in 15% of VasQ patients as opposed to 50% of control (P = .04). The end result was 100% of VasQ patients who required hemodialysis during the 6-month study period received it via their fistula as compared to 56% of patients in the control patients (P = .01). No safety issues were detected when comparing patients implanted with VasQ as compared to the control.

Principal investigator Dr. Nikolaos Karydis of Guy’s and St Thomas’ said,” Rarely do you observe such a stark difference in outcomes between new technology and the standard of care in dialysis access, a notoriously challenging patient population. The results suggest that VasQ has the potential to dramatically improve our global fistula outcomes for the betterment of our patients. If physician can consistently achieve functional patency as demonstrated in this study, we may avoid repeat interventions and prolonged exposure of patients to the high mortality risks of alternative therapies such as central venous catheters.”

Laminate CEO Tammy Gilon stated, “The results of this randomized-controlled study are very encouraging and an important step to validating the benefits of external support for the application in dialysis patients worldwide. We are grateful to the investigators in our studies for leading the way in changing how fistulas are created.”


Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

By using this website you agree to accept Medical Device News Magazine Privacy Policy